- Home
- CYCN vs AIMD Comparison
CYCN vs AIMD Comparison
Compare CYCN & AIMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CYCN | AIMD |
|---|---|---|
| Founded | 2018 | 1984 |
| Country | United States | United States |
| Employees | N/A | 44 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6M | 10.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CYCN | AIMD |
|---|---|---|
| Price | $1.50 | $2.23 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 55.1K | 37.1K |
| Earning Date | 11-12-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,855,000.00 | $113,037.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1371.65 | 178.19 |
| 52 Week Low | $1.28 | $1.78 |
| 52 Week High | $6.25 | $5.00 |
Technical Indicators
Market Signals| Indicator | CYCN | AIMD |
|---|---|---|
| Relative Strength Index (RSI) | 41.63 | 43.87 |
| Support Level | $1.63 | $2.12 |
| Resistance Level | $1.77 | $2.56 |
| Average True Range (ATR) | 0.11 | 0.18 |
| MACD | 0.03 | 0.06 |
| Stochastic Oscillator | 20.51 | 62.82 |
Price Performance
Historical ComparisonAbout CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.
About AIMD Ainos Inc.
Ainos Inc is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics. Its AI Nose platform and smell language model (SLM) digitize scent into Smell ID, a machine-readable data format, powering intelligent sensing across robotics, smart factories, and healthcare. The company also develops VELDONA, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases. It combines AI and Nose, redefining machine perception for the sensory age.